Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10676751 | 0.83 | NOTUM (0.36) | KDM4EALDH1A1L3MBTL1MEN1OPRM1 | |
| SCHEMBL6104782 | 0.81 | ACSS2 (0.34) | TDP1MEN1OPRM1OPRD1KMT2A | |
| SCHEMBL950593 | 0.80 | TNF (0.31) | — | |
| SCHEMBL3502260 | 0.79 | GRN (0.34) | MEN1OPRM1OPRD1KMT2ASMN1; SMN2 | |
| SCHEMBL10456979 | 0.77 | SMN1; SMN2 (0.36) | KDM4ETDP1MEN1KMT2ACYP19A1 | |
| SCHEMBL6105313 | 0.76 | ALDH1A1 (0.36) | KDM4EALDH1A1KMT2ACYP2C19HIF1A | |
| SCHEMBL3503135 | 0.75 | BRS3 (0.35) | — | |
| SCHEMBL7715187 | 0.75 | ALDH1A1 (0.34) | KDM4EALDH1A1TDP1MEN1OPRM1 | |
| SCHEMBL3501940 | 0.74 | — | — | |
| SCHEMBL3502442 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-7691859-B2 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2010-04-06 | — | — | US | disclosed |
| EP-1382607-B1 | Prenyl transferase inhibitors | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20080176835-A1 | Prenyl Transferase Inhibitors | BIOMEASURE, INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-7361656-B2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7084135-B1 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2006-08-01 | — | — | US | disclosed |
| US-20060142275-A1 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1140942-B1 | PRENYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-10 | — | — | EP | disclosed |
| EP-1382607-A2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176835-A1 | Prenyl Transferase Inhibitors | FNTA, FNTB, RCE1 | KDM4E 1956/4885ALDH1A1 3942/4885POLB 3510/4885 |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | KDM4E 1159/4885ALDH1A1 1228/4885POLB 3240/4885 |
| US-20060142275-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | KDM4E 1956/4885ALDH1A1 3942/4885POLB 3510/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | KDM4E 1159/4885ALDH1A1 1228/4885POLB 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.